|Application ||WB, IHC-P, IF|
|Dilution||IHC-P (5 µg/ml), WB (1-2 µg/ml),|
|Other Names||Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, p57Kip2, CDKN1C, KIP2|
|Target/Specificity||Human CDKN1C / p57 Kip2. At least three isoforms of CDKN1C are known to exist; this antibody will detect all three isoforms. Despite its predicted molecular weight, CDKN1C often migrates at 57kD in SDS-PAGE. CDKN1C antibody is predicted to not cross ...|
|Reconstitution & Storage||Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.|
|Precautions||CDKN1C / p57 Kip2 Antibody (N-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non- proliferative state throughout life.|
|Tissue Location||Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non- proliferative state throughout life.
Matsuoka S.,et al.Genes Dev. 9:650-662(1995).
Reid L.H.,et al.Cancer Res. 56:1214-1218(1996).
Tokino T.,et al.Hum. Genet. 97:625-631(1996).
Lam W.W.K.,et al.J. Med. Genet. 36:518-523(1999).
Dephoure N.,et al.Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.